Pure Biologics S.A. (WSE: PUR)
Poland
· Delayed Price · Currency is PLN 20.20
-0.60 (-2.88%)
Sep 27, 2024, 5:04 PM CET
Pure Biologics Income Statement
Financials in millions PLN. Fiscal year is January - December.
Millions PLN. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
| Revenue | 0.07 | 0.1 | 0.66 | 0.25 | 0.57 | 1.78 | Upgrade
|
| Revenue Growth (YoY) | -88.04% | -85.65% | 160.63% | -55.59% | -67.79% | 39.24% | Upgrade
|
| Cost of Revenue | 1.75 | 2.67 | 6.07 | 4.28 | 4.51 | 0.68 | Upgrade
|
| Gross Profit | -1.68 | -2.57 | -5.41 | -4.03 | -3.94 | 1.1 | Upgrade
|
| Selling, General & Admin | 34 | 38.01 | 28.71 | 20.69 | 20.46 | 4.67 | Upgrade
|
| Research & Development | - | - | - | - | - | 12.24 | Upgrade
|
| Other Operating Expenses | -11.82 | -16.25 | -11.93 | -17.15 | -15.95 | -11.94 | Upgrade
|
| Operating Expenses | 26.76 | 27.54 | 19.28 | 6.46 | 7.62 | 4.97 | Upgrade
|
| Operating Income | -28.44 | -30.12 | -24.68 | -10.49 | -11.56 | -3.87 | Upgrade
|
| Interest Expense | -3.3 | -3.83 | -0.33 | -0.23 | -0.35 | -0.3 | Upgrade
|
| Interest & Investment Income | 0.14 | 0.28 | 0.2 | 0.09 | 0.03 | 0 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.41 | -0.41 | -0.02 | -0.06 | 0.12 | -0.03 | Upgrade
|
| Other Non Operating Income (Expenses) | 0 | 0 | - | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -32.01 | -34.08 | -24.83 | -10.69 | -11.76 | -4.2 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.02 | -0.02 | -0.82 | -1.09 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.01 | 0.01 | 0.05 | 0.01 | - | - | Upgrade
|
| Other Unusual Items | -1.62 | -1.62 | - | - | - | - | Upgrade
|
| Pretax Income | -33.63 | -35.69 | -25.6 | -11.77 | -11.76 | -4.2 | Upgrade
|
| Net Income | -33.62 | -35.69 | -25.6 | -11.77 | -11.76 | -4.2 | Upgrade
|
| Net Income to Common | -33.62 | -35.69 | -25.6 | -11.77 | -11.76 | -4.2 | Upgrade
|
| Shares Outstanding (Basic) | 3 | 3 | 2 | 2 | 2 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 3 | 3 | 2 | 2 | 2 | 2 | Upgrade
|
| Shares Change (YoY) | 32.26% | 41.50% | 1.48% | 34.29% | 8.48% | 38.63% | Upgrade
|
| EPS (Basic) | -10.34 | -11.19 | -11.36 | -5.30 | -7.11 | -2.75 | Upgrade
|
| EPS (Diluted) | -10.34 | -11.19 | -11.36 | -5.30 | -7.11 | -2.75 | Upgrade
|
| Free Cash Flow | -16.06 | -23.44 | -23.15 | -24.71 | -1.91 | 6.64 | Upgrade
|
| Free Cash Flow Per Share | -4.94 | -7.35 | -10.27 | -11.12 | -1.16 | 4.35 | Upgrade
|
| Gross Margin | - | - | - | - | - | 61.88% | Upgrade
|
| Operating Margin | -41221.74% | -31702.11% | -3728.40% | -4129.13% | -2020.10% | -217.91% | Upgrade
|
| Profit Margin | -48724.64% | -37572.63% | -3867.52% | -4631.89% | -2055.24% | -236.20% | Upgrade
|
| Free Cash Flow Margin | -23276.81% | -24671.58% | -3496.22% | -9727.56% | -334.62% | 373.87% | Upgrade
|
| EBITDA | -22.94 | -24.37 | -22.46 | -7.84 | -8.66 | -1.9 | Upgrade
|
| EBITDA Margin | - | - | - | - | - | -106.76% | Upgrade
|
| D&A For EBITDA | 5.5 | 5.75 | 2.23 | 2.65 | 2.9 | 1.97 | Upgrade
|
| EBIT | -28.44 | -30.12 | -24.68 | -10.49 | -11.56 | -3.87 | Upgrade
|
| EBIT Margin | - | - | - | - | - | -217.91% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.